Donna L Senger

List of Publications by Year
in descending order

38 papers	2,381 citations	218677 26 h-index	345221 36 g-index
38 all docs	38 docs citations	38 times ranked	3370 citing authors

#	Article	IF	Citations
1	Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. Science Advances, 2022, 8, eabm0142.	10.3	28
2	To promote or inhibit glioma progression, that is the question for IL-33. Cell Stress, 2021, 5, 19-22.	3.2	2
3	Overcoming therapeutic resistance in glioblastoma: Moving beyond the sole targeting of the glioma cells. , 2021, , 91-118.		0
4	Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumour stem cells (BTSCs). Biochemistry and Cell Biology, 2020, 98, 647-652.	2.0	4
5	Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nature Communications, 2020, 11, 4997.	12.8	109
6	Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials, 2020, 252, 120105.	11.4	15
7	Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver. Cell, 2019, 178, 1205-1221.e17.	28.9	80
8	Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19098-19108.	7.1	42
9	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Research, 2019, 79, 2111-2123.	0.9	28
10	A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth. Cell Chemical Biology, 2018, 25, 1485-1494.e5.	5.2	20
11	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE, 2018, 13, e0202860.	2.5	28
12	Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. Journal of Clinical Investigation, 2018, 128, 2894-2913.	8.2	74
13	Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nature Communications, 2017, 8, .	12.8	103
14	Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells. Cancer Research, 2017, 77, 3231-3243.	0.9	61
15	Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget, 2016, 7, 59360-59376.	1.8	34
16	N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells. Molecular Therapy - Oncolytics, 2016, 3, 16005.	4.4	2
17	Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clinical Cancer Research, 2016, 22, 3860-3875.	7.0	142
18	MTR-08MODELING TMZ RESISTANCE IN PATIENT-DERIVED BRAIN TUMOR- INITIATING CELLS. Neuro-Oncology, 2015, 17, v125.4-v126.	1.2	0

#	Article	IF	Citations
19	QuantitativeT2: interactive quantitative T2 MRI witnessed in mouse glioblastoma. Journal of Medical Imaging, 2015, 2, 1.	1.5	8
20	Novel <i>MSH6</i> Mutations in Treatment-NaÃ¯ve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of <i>MGMT</i> Promoter Methylation. Clinical Cancer Research, 2014, 20, 4894-4903.	7.0	51
21	Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro-Oncology, 2013, 15, 904-920.	1.2	44
22	Assessing Mechanisms of Glioblastoma Invasion. Neuromethods, 2012, , 275-298.	0.3	1
23	Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma. Molecular Therapy, 2010, 18, 1927-1936.	8.2	83
24	Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin. Cancer Research, 2010, 70, 598-608.	0.9	90
25	Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens. Stem Cells, 2009, 27, 1722-1733.	3.2	175
26	Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide. Clinical Cancer Research, 2009, 15, 2777-2788.	7.0	142
27	Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors. Clinical Cancer Research, 2008, 14, 1218-1227.	7.0	47
28	Gamma-Secretase Represents a Therapeutic Target for the Treatment of Invasive Glioma Mediated by the p75 Neurotrophin Receptor. PLoS Biology, 2008, 6, e289.	5.6	66
29	The p75 Neurotrophin Receptor Is a Central Regulator of Glioma Invasion. PLoS Biology, 2007, 5, e212.	5.6	150
30	Proteolytic Disassembly Is a Critical Determinant for Reovirus Oncolysis. Molecular Therapy, 2007, 15, 1512-1521.	8.2	76
31	Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Cancer Research, 2007, 67, 8818-8827.	0.9	97
32	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV Î”M51) on Multifocal and Invasive Gliomas. Journal of the National Cancer Institute, 2006, 98, 1546-1557.	6.3	88
33	Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas. Cancer Research, 2005, 65, 9982-9990.	0.9	149
34	Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals. Clinical Cancer Research, 2004, 10, 8561-8576.	7.0	78
35	Spatial requirements for TrkA kinase activity in the support of neuronal survival and axon growth in rat sympathetic neurons. Neuropharmacology, 2003, 45, 995-1010.	4.1	33
36	Rapid Retrograde Tyrosine Phosphorylation of trkA and Other Proteins in Rat Sympathetic Neurons in Compartmented Cultures. Journal of Cell Biology, 1997, 138, 411-421.	5.2	153

#	Article	IF	Citations
37	Spatial Regulation of Neuronal Gene Expression in Response to Nerve Growth Factor. Developmental Biology, 1997, 184, 1-9.	2.0	31
38	Evidence that Protein Kinase C Activities Involved in Regulating Neurite Growth Are Localized to Distal Neurites. Journal of Neurochemistry, 1994, 63, 868-878.	3.9	47